Eli Lilly and Company $LLY Shares Sold by GW&K Investment Management LLC

GW&K Investment Management LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,478 shares of the company’s stock after selling 1,341 shares during the quarter. GW&K Investment Management LLC’s holdings in Eli Lilly and Company were worth $23,082,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after purchasing an additional 1,006,885 shares in the last quarter. State Street Corp lifted its position in shares of Eli Lilly and Company by 0.6% during the third quarter. State Street Corp now owns 34,726,558 shares of the company’s stock worth $26,496,364,000 after purchasing an additional 219,590 shares in the last quarter. Capital Research Global Investors lifted its position in shares of Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares in the last quarter. Capital World Investors lifted its position in shares of Eli Lilly and Company by 0.4% during the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after purchasing an additional 61,851 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of Eli Lilly and Company by 4.1% during the third quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock worth $11,112,164,000 after purchasing an additional 574,229 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.5%

LLY stock opened at $1,138.78 on Thursday. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,182.73. The company’s 50 day moving average is $989.96 and its two-hundred day moving average is $1,015.14. The stock has a market cap of $1.07 trillion, a P/E ratio of 40.45, a PEG ratio of 1.25 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter last year, the company earned $3.34 earnings per share. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were issued a dividend of $1.73 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA approved extended every-8-weeks maintenance dosing for EBGLYSS, improving convenience and potentially boosting adoption in Lilly’s dermatology business.
• Positive Sentiment: Reuters reported that Lilly is still viewed as the leader in the fast-growing obesity-drug market, even as rivals rush into the space, reinforcing confidence in its competitive moat. Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
• Positive Sentiment: Recent coverage also highlighted positive Phase 3 data for retatrutide and favorable Foundayo (orforglipron) weight-loss results, keeping investor enthusiasm high around Lilly’s obesity pipeline.
• Positive Sentiment: Jefferies raised its price target on LLY to $1,350 and reiterated a Buy rating, signaling continued analyst confidence in the stock’s runway. Is Eli Lilly and Company (LLY) One of the 10 Best Dividend Stocks to Buy According to D. E. Shaw?
• Positive Sentiment: Lilly also announced a new Alzheimer’s collaboration with AlzeCure, expanding its neuroscience pipeline and adding another potential long-term growth opportunity.
• Neutral Sentiment: Several articles were commentary pieces or portfolio lists that reinforce Lilly’s reputation as a high-quality defensive growth name, but they do not add materially new fundamental information.

Analyst Ratings Changes

LLY has been the topic of several research reports. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday. Guggenheim reissued a “buy” rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Bank of America raised their target price on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Weiss Ratings cut shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, May 19th. Finally, HSBC cut shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their target price for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.74.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.